Sionna Therapeutics (NASDAQ:SION) entered 2026 with a substantial financial cushion, reporting $310.3 million in cash, cash equivalents, and marketable securities as of December 31, 2025.
The Boston-based biotechnology company, which specializes in developing highly potent small molecules to fully restore CFTR function, confirmed that its current liquidity is sufficient to fund operations into 2028, covering several pivotal clinical milestones.
The company's primary focus is the ongoing PreciSION CF Phase 2a trial of SION-719, a first-in-class NBD1 (nucleotide-binding domain 1) stabilizer.
SION-719 is designed to address the primary defect in the Delta F508 mutation, the most common cause of cystic fibrosis.
Simultaneously, Sionna is advancing a Phase 1 trial of SION-451, a complementary ICL4 stabilizer, in a dual-combination study.
Management reiterated on Monday that topline data for both clinical programs remain on track for release in mid-2026.
Financially, Sionna reported an increased net loss for fiscal 2025, driven by a significant ramp-up in research and development and higher general and administrative expenses.
The rise in spending reflects the transition of multiple candidates into mid-stage clinical testing and the expansion of the company's internal infrastructure to support its maturing pipeline.
Beyond its lead candidates, Sionna continues to progress its "triplet" combination strategy, which aims to achieve wild-type levels of CFTR function by targeting multiple domains of the protein simultaneously.
The company expects to provide further clarity on the clinical commencement of its triple-combination regimens following the mid-2026 readouts of its current dual-therapy and monotherapy studies.